MGMT and central nervous system cancer: Further, we evaluated the association of quantitative contrast enhancement with prognostic molecular markers such as isocitrate dehydrogenase (IDH) and O6-methylguanine-DNA-methyltransferase (MGMT) status in gliomas [8,21].